Cytek Biosciences, Inc. (CTKB)

NASDAQ: CTKB · Real-Time Price · USD
5.46
-0.03 (-0.55%)
Jan 17, 2025, 4:00 PM EST - Market closed
-0.55%
Market Cap 703.31M
Revenue (ttm) 201.21M
Net Income (ttm) -10.16M
Shares Out 128.81M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE 29.51
Dividend n/a
Ex-Dividend Date n/a
Volume 679,850
Open 5.53
Previous Close 5.49
Day's Range 5.41 - 5.60
52-Week Range 4.66 - 9.33
Beta 1.44
Analysts Strong Buy
Price Target 9.25 (+69.41%)
Earnings Date Feb 26, 2025

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS ... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jul 23, 2021
Employees 676
Stock Exchange NASDAQ
Ticker Symbol CTKB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CTKB stock is "Strong Buy." The 12-month stock price forecast is $9.25, which is an increase of 69.41% from the latest price.

Price Target
$9.25
(69.41% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Upgrading Cytek Biosciences Stock On An Upcoming Catalyst

I'm upgrading Cytek Biosciences from "Hold" to "Buy" due to improving financials, expanding installed base, and strong demand for Aurora and Northern Lights systems. Cytek's Q3 FY2024 revenue up 7% Yo...

11 days ago - Seeking Alpha

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...

18 days ago - GlobeNewsWire

Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock r...

21 days ago - GlobeNewsWire

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...

2 months ago - GlobeNewsWire

Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Brea...

2 months ago - GlobeNewsWire

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system.

2 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer Willia...

2 months ago - Seeking Alpha

Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe

FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year's premier clinical industry events across the globe.

4 months ago - GlobeNewsWire

Cytek Announces Resignation of Chief Operating Officer Chris Williams

FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams,...

4 months ago - GlobeNewsWire

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality M...

5 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William ...

5 months ago - Seeking Alpha

Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm

Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes.

6 months ago - GlobeNewsWire

Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference

FREMONT, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming G...

8 months ago - GlobeNewsWire

1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China

FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medica...

8 months ago - GlobeNewsWire

Lab Instrument Industry Update - New Commercial Entrants

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry h...

8 months ago - Seeking Alpha

Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems

FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detec...

8 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McC...

9 months ago - Seeking Alpha

Cytek Biosciences Reports First Quarter 2024 Financial Results

FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...

9 months ago - GlobeNewsWire

Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe

FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by...

9 months ago - GlobeNewsWire

Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024

FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the first qu...

9 months ago - GlobeNewsWire

Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader

Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth a...

10 months ago - Seeking Alpha

Cytek® Biosciences Names William McCombe Chief Financial Officer

Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences...

10 months ago - GlobeNewsWire

Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions

Cytek Biosciences has opened a 50,000-square-foot facility in Wuxi, China to meet the growing worldwide demand for comprehensive cell analysis solutions

11 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript

11 months ago - Seeking Alpha

Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

FREMONT, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...

11 months ago - GlobeNewsWire